Navigation Links
Advantage India: Growth Pills Abound For Pharma Companies

It's advantage Indian pharma companies and the needy patients who would have to fork out much less to purchase life-saving drugs, with global pharma giants like Merck and Pfizer losing// their patent on drugs commanding multi-billion annual sales.

Domestic pharma majors Ranbaxy and Dr Reddy's Laboratories are being touted as major beneficiaries to tap on a multi-billion dollar sales vacuum created by the patent expiry of two biggest blockbuster drugs in the US -- cholesterol- cutting drug Zocor and antidepressant Zoloft -- within the span of a week.

Merck's patent for Zocor that contributed USD 4.4 billion in the company's 2005 sales expired on June 23, while Pfizer loses its patent for Zoloft, which totalled USD 3.3 billion in 2005 sales, on June 30.

When a company loses its exclusive patent for a branded drug, market opens to a host of generic drugmakers that leads to a drop of nearly 80 per cent in the drug's price, which results in a major gain for consumers as well as the makers of generic version of these drugs.

While analysts expect good value addition in share prices of DRL and Ranbaxy on the back of patent related global news flow going forward, another pharma major Cipla has already outperformed the Sensex since June 14, when the 30-share barometer index had plummeted to its lowest level in past few months at 8,799.01.

Cipla has gained 17.91 per cent since June 14 as against a gain of 16.48 per cent in Sensex. Ranbaxy on the other hand rose 11.01 per cent and DRL 8.51 per cent during the same period.

Source:PTI News
'"/>




Page: 1

Related medicine news :

1. Advantages of Red Wine
2. Inactivation of Rad9 in Tumor Cells Would Be Advantageous In Cancer Therapy
3. Competitive Advantage Are Attained In Which Freeloaders Are Punished
4. Retro Running Is Found To Be More Advantageous
5. New Antipsychotic Medications have Little Advantage Over Older Drugs
6. "New" Clear Advantages In Nuclear Medicine
7. HIV Takes Advantage of Rivalry among T cells
8. Advantage Coffee and Disadvantage-Diabetes
9. Obesity - An Advantage For MHD Patients
10. Advantage, Obese Men!!
11. Vitamin A supplementation inadequate in India: Need for effective strategies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it came ... contact center in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand ... recently invested $51 million to purchase and renovate the 185,000 square-foot office complex, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... to fewer trips the emergency room, fewer hospital admissions, and better blood pressure ... Managed Care® (AJMC®) finds. The study can be found here . , ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Prosthetic Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 9.2% over the next ... industry report analyzes the market estimates and forecasts for all the ...
(Date:2/23/2017)... 23, 2017 MabVax Therapeutics Holdings, ... development company, announces that it has received notice ... authorizing the initiation a Phase I clinical trial ... cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s ... to initiate the phase I clinical trial in ...
(Date:2/23/2017)... , Feb. 22, 2017 Orthopedic ... implant demand, as aging demographic patterns lead to ... Implants for sports- and exercise-related injuries, chronic back ... will lead sales gains. The future of medical ... addresses the following questions and more: - ...
Breaking Medicine Technology: